Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 3Completed 2

Sponsor Class

NIH 3OTHER 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Ovarian Neoplasms 5Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Glioblastoma 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uveal Melanoma 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hypertension 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × cediranib × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02345265 2026-05-28

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
123 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

AstraZeneca

Phase 2 Completed
62 enrolled 15 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡